Table of Contents
Chemotherapy Research and Practice
Volume 2017 (2017), Article ID 8196434, 4 pages
https://doi.org/10.1155/2017/8196434
Clinical Study

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

1Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
2Centre for Cancer Epidemiology, ACTREC, Tata Memorial Centre, Mumbai, India
3Department of Pathology, Tata Memorial Hospital, Mumbai, India
4Department of Radiology, Tata Memorial Hospital, Mumbai, India
5Department of Nuclear Medicine, Tata Memorial Hospital, Mumbai, India

Correspondence should be addressed to Kumar Prabhash

Received 18 April 2017; Revised 6 September 2017; Accepted 26 September 2017; Published 23 October 2017

Academic Editor: Naoya Fujita

Copyright © 2017 Amit Joshi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. S. Ettinger, W. Akerley, H. Borghaei et al., “Non–Small Cell Lung Cancer,” Journal of the National Comprehensive Cancer Network, vol. 11, pp. 645–653, 2013. View at Publisher · View at Google Scholar
  2. R. Rosell, E. Carcereny, R. Gervais et al., “Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial,” The Lancet Oncology, vol. 13, pp. 239–246, 2012. View at Google Scholar
  3. M. Maemondo, A. Inoue, K. Kobayashi et al., “Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR,” The New England Journal of Medicine, vol. 362, no. 25, pp. 2380–2388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. V. A. Miller, V. Hirsh, J. Cadranel et al., “Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial,” The Lancet Oncology, vol. 13, no. 5, pp. 528–538, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. F.-C. Kuan, L.-T. Kuo, M.-C. Chen et al., “Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis,” British Journal of Cancer, vol. 113, no. 10, pp. 1519–1528, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. V. M. Patil, V. Noronha, A. Joshi et al., “Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma,” ESMO Open, vol. 2, no. 1, p. e000168, 2017. View at Publisher · View at Google Scholar
  7. S. V. Sharma, D. W. Bell, J. Settleman, and D. A. Haber, “Epidermal growth factor receptor mutations in lung cancer,” Nature Reviews Cancer, vol. 7, no. 3, pp. 169–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Li, Q. Zhang, L. Liu et al., “The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China,” Neoplasma, vol. 58, no. 1, pp. 74–81, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. C.-H. Yang, Y.-L. Wu, M. Schuler et al., “Afatinib versus cisplatin-based Chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials,” The Lancet Oncology, vol. 16, no. 2, pp. 141–151, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Kogure, H. Saka, and M. Oki, Efficacy of pemetrexed for EGFR mutated lung carcinoma between L858R and Exon 19 deletion, 2015, http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.e19073.
  11. V. Talreja, V. Noronha, V. Patil et al., “P3.02b-055 impact of pemetrexed chemotherapy in exon 19 or exon 21 mutated NSCLC,” Journal of Thoracic Oncology, vol. 12, no. 1, p. S1223, 2017. View at Publisher · View at Google Scholar
  12. C.-H. Yun, K. E. Mengwasser, A. V. Toms et al., “The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 105, no. 6, pp. 2070–2075, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. E. Arcila, G. R. Oxnard, K. Nafa et al., “Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay,” Clinical Cancer Research, vol. 17, no. 5, pp. 1169–1180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Ma, S. Wei, and Y. Song, “T790M and acquired resistance of EGFR TKI: a literature review of clinical reports,” Journal of Thoracic Disease, vol. 3, no. 1, pp. 10–18, 2011. View at Publisher · View at Google Scholar · View at Scopus